AJSNS: Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome

Sponsor
Rabin Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT02649413
Collaborator
(none)
75
1
1
39
1.9

Study Details

Study Description

Brief Summary

The initial steroids dose for Nephrotic Syndrome is 60mg/1m2 for 6-4 weeks and the duration of the first steroid course is between 8 weeks to 6 months. The base of the initial dose for steroids Idiopathic nephrotic syndrome been put in the early 70s. In our study the investigators will adjusted the first steroids does to the response day. Our primary end point is : a lower adjusted dose is as good as the fix dose in the first year after diagnosis.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

About 90% of the patients will response to steroid therapy. The initial steroid dose is between 2mg/kg or 60mg/1m2 for 6-4 weeks and the duration of the first steroid course is between 8 weeks to 6 months. The bases of this treatment have been put in the early 70s. Since then most of the study were focused on the duration of the therapy with a results that 8-12 weeks course is as good as 6 month. Studies have showed no difference in response rate between 2mg/kg to 60m2' although the difference in the dose in young children can rich to 25%. Other retrospective analysis been show that patients who response in the first 7-9 days tend to have lass relapses than other patients. In our nephrology clinic the investigators there is ongoing clinical study on low doses of steroid therapy for relapse of nephritic syndrome with good results.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Adjusted Steroid Therapy in Children With Idiopathic Nephrotic Syndrome
Study Start Date :
Mar 1, 2016
Anticipated Primary Completion Date :
Apr 1, 2019
Anticipated Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Early response to prednisone treatment

intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.

Drug: Prednisone
Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
Other Names:
  • corticosteroids
  • Outcome Measures

    Primary Outcome Measures

    1. The time until the first relapse [6 months]

      All Children with Nephrotic Syndrome will start a dose of 60 mg/m2 prednisone.patients that will response in 8 days (the first day with a negative or trace in the urine deep stick test)will receive adjusted lower steroid dose.the outcome is the time until the first relapse( positive protein in deep stick urine test,or low serum albumin with positive urine deep stick).the control group is the historical data from a prospective malty center observation study.

    Secondary Outcome Measures

    1. Number of relapse during first year [one year]

      We will count the number of relapse episodes in the first year since diagnosis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Children who recently have been diagnosed with nephrotic syndrome.
    Exclusion Criteria:
    • Children with nephrotic syndrome that can not be treated with steroids.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shneider children Hospital Nephrology Institute Petach-Tikva Israel

    Sponsors and Collaborators

    • Rabin Medical Center

    Investigators

    • Principal Investigator: Amit Dagan, Dr., Shneider children Hospital Nephrology Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Rabin Medical Center
    ClinicalTrials.gov Identifier:
    NCT02649413
    Other Study ID Numbers:
    • 695 RMC -AJSNS
    First Posted:
    Jan 7, 2016
    Last Update Posted:
    Jan 12, 2016
    Last Verified:
    Dec 1, 2015
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 12, 2016